MedTrace Logo

Scandinavian Intensive Care Unit (ICU) Glutamine Study

NCT00922714 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2009-06-17

No results posted yet for this study

Summary

This is a prospective double-blinded placebo-controlled block randomized study in intensive care patients comparing intravenous glutamine supplementation to placebo. The hypothesis is an improvement of clinical outcome. The primary endpoint is a reduction in the Sequential Organ Failure Assessment (SOFA) score on day 7 of treatment.

Conditions

  • ICU Patients

Interventions

DRUG

Glutamine

Intravenous glutamine supplementation (0.285 g/kg body weight/24 h)

DRUG

saline (placebo)

NaCl 0.9 g/L

Sponsors & Collaborators

  • Scandinavian Critical Care Trials Group

    lead OTHER

Principal Investigators

  • Jan Wernerman, MD, PhD · Dept Anesthesiology and Intensive Care Medicine, KArolinska University Hospital Huddinge, Stockholm, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-10-31
Primary Completion
2007-05-31
Completion
2009-08-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00922714 on ClinicalTrials.gov